摘要
目的评估手术联合新辅助化疗治疗局部晚期食管癌的疗效及生存时间。方法收集2010年4月~2012年2月间本院收治的局部晚期食管癌患者88例,按照随机数表法将入组患者分为对照组(n=44)、观察组(n=44)。对照组患者接受常规手术治疗,观察组患者接受新辅助化疗联合手术治疗,对比两组术前、术后3月血清肿瘤标志物及血管新生指标的含量差异,进行随访并记录两组患者的中位生存时间及1年、5年生存率。结果术前,两组患者血清肿瘤标志物、血管新生指标含量的差异无统计学意义(P>0.05)。术后3月,观察组患者血清肿瘤标志物YY1、TSGF、Cyfra21-1以及血管新生指标TGF-β1、VEGF、MMP-9的含量均显著低于对照组患者(P<0.05)。随访期间,观察组患者的中位生存时间长于对照组患者,术后1年、5年生存率高于对照组患者(P<0.05)。结论新辅助化疗联合手术治疗局部晚期食管癌,可降低肿瘤恶性程度,延长患者生存时间。
Objective To evaluate the treatment effect and the survival time of operation combined with neoadjuvant chemotherapy in locally advanced esophageal carcinoma patients. Methods 88 locally advanced esophageal carcinoma patients were enrolled between April 2010 and February 2012 in our hospital and randomly divided into control group （n =44） and observation group （n =44）. Patients in control group received routine treatment and patients in observation group were treated with operation combined with neoadjuvant chemotherapy. The levels of serum tumor markers and contents of angiogenesis indices were compared before and after surgery for three months between the two groups. All patients were followed up for 5 years. And the postoperative median survival time, 1-year and 5-year survival rates were also recorded and compared. Results Before operation, there were no significant differences between the two groups in the levels of serum tumor markers and angiogenesis indices （P〉0.05）. Three months after surgery, serum contents of tumor markers YY1, TSGF, Cyfra21-1 in observation group were lower than those in control group, while the contents of TGF- 1, VEGF, MMP-9 in observation group were signifi- cantly lower than those in control group （P〈0.05）. During the follow-up period, the median survival time of observation group was longer than that of control group, and the 1-year and 5-year survival rates of observation group after operation were higher than those of the control group （P〈 0.05）. Conclusion Operation combined with neoadjuvant chemotherapy in the treatment of locally advanced esophageal cancer patients is hdpful to reduce the malignant degree of tumor and prolong the survival time of patients.
作者
张宇琳
吴涛
刘鸿翔
唐猛
张现普
ZHANG Yulin WU Tao LIU Hongxiang TANG Meng ZHANG Xianpu(Department of Oncology, Chongqing Cancer Institute, Chongqing, 400030, China Department of Thoracic Surgery, the First Affiliated Hospital of Third Military Medical University, Chongqing, 400038, China)
出处
《肿瘤药学》
CAS
2017年第3期300-303,共4页
Anti-Tumor Pharmacy
基金
国家自然科学基金资助项目(30872464)
关键词
局部晚期食管癌
新辅助化疗
肿瘤标志物
血管新生
生存时间
Locally advanced esophageal carcinoma
Neoadjuvant chemotherapy
Tumor marker
Angiogenesis
Survival time
